News

Schafer Boeder, MD describes the potential role and safety of adjunctive therapy, including SGLT2 inhibitors and GLP-1 agonists, for patients with T1D.

Efficacy and safety of brilaroxazine for schizophrenia sustained for > 1 year in open-label extension of RECOVER, announced by Reviva Pharmaceuticals.

The approval of tapinarof cream (Vtama) for patients aged 2 years and older with eczema follows the positive findings in the ADORING trial program.

This approval announcement by Galderma follows the previous FDA approval of nemolizumab for prurigo nodularis.

In this episode, hosts reflect on the advancement in CGM that reshaped care for diabetes and overall health during 2024.

Real-world data from 18,710 MASH patients highlight the impact of comorbidities, biomarkers, and region on mortality, with 70% of deaths CVD-related.

Machine learning models improve accuracy in detecting MASH with F2-F3 fibrosis, surpassing noninvasive tests in sensitivity, specificity, and predictive value.

Observational data point to aldosterone dysregulation as an underrecognized risk factor for hypertension and confirm T2D as a known risk factor.

Alice Cheng, MD, discusses the impact of diabetes on cognitive function and the emerging role of diabetic drug classes in dementia care.

Matthew J. Budoff, MD discusses the effects of obesity and cardiometabolic complications in the contemporary management of type 1 diabetes.

Crinecerfont is indicated to be used with glucocorticoids to control androgen levels in adults and pediatric patients with classic congenital adrenal hyperplasia.

Jennifer B. Green, MD highlights the successful implementation of evidence-based therapies for high-risk patients with type 2 diabetes.

This interim analysis highlights positive findings from the Measure Up 1 and 2 studies regarding upadacitinib for patients with atopic dermatitis.

Ralph A. DeFronzo, MD discusses the Noxious Nine and the impact of hypercortisolism on difficult-to-control type 2 diabetes.

A study finds that therapists deliver high-quality CBT in routine psychiatric care but found no evidence that therapist adherence and competence correlate to patient outcomes.

Matthew Weir, MD discusses how a multidisciplinary approach is reshaping CKD management, with a focus on mitigating cardiovascular events.

Lower CD4+ cell counts, HCV genotype 4, and recent injection drug use were linked to unsuccessful DAA treatment in people with HCV and HIV.

These data provide insight into characteristics of those who choose to discontinue systemic therapies for eczema.

Matsushita discussed findings from the OLE FRONTIER4 study of Mim8.

The AASM has updated its RLS guidelines, now recommending against the standard use of dopamine agonists due to evidence of augmentation.

Despite having a lower risk of hospitalization, cardiovascular events, and mortality, patients with IgAN and FSGS had a higher risk of CKD progression.

America's mental health crisis continues to escalate—what drives it, and what lies ahead in 2025? Hear insight from psychiatry and psychology experts.

Erin Michos, MD examines unique HFpEF mechanisms for women and implications for sex-specific treatment.

Matino discussed data from the phase 3 BASIS study evaluating the recently approved Hympavzi.

Patients with hypercortisolism and difficult-to-control type 2 diabetes who received mifepristone exhibited a significant HbA1c improvement in the Phase 4 trial.

The FDA awarded Breakthrough Therapy Designation to Vir Biotechnology’s tobevibart and elebsiran for the treatment of chronic hepatitis delta.

This assessment of dupilumab for pediatric and adult patients with moderate-to severe eczema treated for up to 5 years confirms the drug efficacy and safety across age groups.

Elevated blood insulin levels and insulin resistance each contributed to an elevated risk of colorectal cancer, a new study finds.